Sugars for the development of more effective protein therapeutics
Small molecule sugar analogues can also be used as inhibitors for the development of more effective biosimilars and biobetters, including therapeutic antibodies, viral vectors, and enzyme replacement therapies. Glycans, unlike proteins and nucleic acids, are not synthesized using a template strand. Using small molecule inhibitors as glycosylation modifiers can be a powerful strategy in altering the glycan presentation on proteins or cells. By selectively targeting enzymes responsible for adding or removing specific sugars from the glycan, these inhibitors enable the production of tailored glycans with precision and ease.
We have developed robust process chemistry around the scale-up and cGMP manufacture of a line of glycosylation modifiers including Kifunensine, 2-Fluorofucose (2-FF), 3-Fluorosialic acid, and an array of imminosugar inhibitors: Deoxynojirimycin (DNJ), Deoxymannojirimycin (DMJ), Deoxygalactonojirimycin (DGJ), and Deoxyfuconojirimycin (DFJ). Moreover, our synthetic expertise positions our organization to make a wide range of proprietary derivatives of these compounds.
If you’re interested in learning more about glycosylation modifiers, we invite you to check out our online catalogue here. You’ll find detailed information on a variety of glycosylation modifiers that can be used to manipulate glycan presentation on proteins or cells.